文献速递淋巴瘤

536例无17p缺失的初治慢性淋巴细胞白血病患者接受化学免疫治疗的两项前瞻性试验中遗传异常的预后影响:聚焦IGHV突变亚组(FILO研究)

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
PubMed 文献 · Br J Haematol · 2024-04-23

该研究对两项前瞻性试验中536例接受一线化学免疫治疗的慢性淋巴细胞白血病患者进行细胞遗传学和靶向二代测序整合分析,评估主要遗传异常的预后意义并按IGHV状态分层。全队列中未突变IGHV、复杂核型、del(11q)和ATM突变与更短无进展生存显著相关;在突变IGHV亚组中,复杂核型、del(11q)、SF3B1和SAMHD1突变与显著更低无进展生存相关,而TP53突变在该亚组无显著影响。

要点

  • 全队列中未突变IGHV、复杂核型、del(11q)和ATM突变与更短PFS显著相关。
  • 突变IGHV亚组中复杂核型、del(11q)、SF3B1和SAMHD1突变与显著更低PFS相关。
  • 上述异常在未突变IGHV亚组中未影响结局,TP53突变在突变IGHV亚组无显著影响。

核心结论

  • 在接受一线化学免疫治疗的症状性慢性淋巴细胞白血病患者中,遗传异常的预后影响因IGHV状态而异。
  • 基因突变和细胞遗传学异常的预后需采用分区方法研究,并考虑接受一线BTK和/或BCL2抑制剂患者的IGHV状态。

研究设计与样本

  • 对两项前瞻性试验中536例接受一线化学(免疫)治疗的慢性淋巴细胞白血病患者,整合细胞遗传学和靶向二代测序所识别的遗传异常进行分析。

主要发现

  • 全队列中未突变IGHV、复杂核型、del(11q)和ATM突变与更短无进展生存显著相关。
  • 突变IGHV亚组单因素分析显示复杂核型、del(11q)、SF3B1和SAMHD1突变与显著更低无进展生存相关。
  • 这些异常在未突变IGHV亚组中未影响结局。
  • TP53突变在突变IGHV亚组中对结局无显著影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative analysis on genetic abnormalities identified through cytogenetics and targeted next-generation sequencing in 536 CLL patients receiving first-line chemo(immuno)therapies (CIT) as part of two prospective trials. We evaluated the prognostic implications of the main abnormalities, with specific attention to their relative impact according to IGHV status. In the entire cohort, unmutated (UM)-IGHV, complex karyotype, del(11q) and ATM mutations correlated significantly with shorter progression-free survival (PFS). Focusing on the subset of mutated IGHV (M-IGHV) patients, univariate analysis showed that complex karyotype, del(11q), SF3B1 and SAMHD1 mutations were associated with significant lower PFS. The prognostic influence varied based on the patient's IGHV status, as these abnormalities did not affect outcomes in the UM-IGHV subgroup. TP53 mutations had no significant impact on outcomes in the M-IGHV subgroup. Our findings highlight the diverse prognostic influence of genetic aberrations depending on the IGHV status in symptomatic CLL patients receiving first-line CIT. The prognosis of gene mutations and cytogenetic abnormalities needs to be investigated with a compartmentalized methodology, taking into account the IGVH status of patients receiving first-line BTK and/or BCL2 inhibitors.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nguyen-Khac F, Baron M, Guièze R, et al. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study). Br J Haematol. 2024. PMID: 38654616. doi:10.1111/bjh.19459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。